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Multiple myeloma (MM), a hematological malignancy characterized by the clonal growth of malignant plasma cells
(PCs) in the bone marrow, is preceded by the benign asymptomatic condition, monoclonal gammopathy of
undetermined significance (MGUS). Several genetic abnormalities have been identified as critical for the development
of MM; however, a number of these abnormalities are also found in patients with MGUS, indicating that there are
other, as yet unidentified, factors that contribute to the onset ofMMdisease. In this study, we identify a Samsn1 gene
deletion in the 5TGM1/C57BL/KaLwRij murine model of myeloma. In addition, SAMSN1 expression is reduced in the
malignant CD138+ PCs of patients with MM and this reduced expression correlates to total PC burden. We identify
promotermethylation as a potential mechanism throughwhich SAMSN1 expression ismodulated in humanmyeloma
cell lines.Notably, re-expression ofSamsn1 in the 5TGM1murinePC line resulted in complete inhibition ofMMdisease
development in vivo and decreased proliferation in stromal cell–PC co-cultures in vitro. This is the first study to identify
deletion of a key gene in the C57BL/KaLwRij mice that also displays reduced gene expression in patientswithMMand
is therefore likely to play an integral role in MM disease development.
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Multiple myeloma (MM) is an incurable hematological malignancy
characterized by the clonal proliferation of malignant plasma cells
(PCs) within the bone marrow (BM). MM is the second most
common hematological malignancy after non-Hodgkin’s lymphoma,
with approximately 20,000 newly diagnosed patients each year
in the USA [1]. The main clinical manifestations of MM are the
development of osteolytic bone lesions, bone pain, hypercalcemia,
renal insufficiency, suppressed immunoglobulin production, and
increased BM angiogenesis. Despite recent advances in treatment,
MM remains almost universally fatal with a 10-year survival rate of
approximately 17% [2].
MM encompasses a range of clinical variants ranging from
monoclonal gammopathy of undetermined significance (MGUS)
and smoldering/indolent MM to more aggressive disseminated forms
of MM and PC leukemia. It is now widely accepted that most, if not
all, MMs are preceded by a premalignant MGUS [3]. MGUS is
defined as a benign proliferation of PCs and is clinically characterizedby the presence of monoclonal protein (or “paraprotein”) of b3 g/dl,
clonal PCs constituting b10% of the BM, and the absence of organ
damage [4]. Patients with MGUS have a risk of developing overt MM
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Figure 1. Global loss of Samsn1 expression is a feature of the 5TGM/C57BL/KaLwRij mouse model of myeloma. (A) The gene expression
profiles of the long bones of C57BL/6 (n = 4) and C57BL/KaLwRij (n = 4) mice were compared using the Illumina Mouse WG-6 v2.0
BeadChip. Fold change in gene expression between the strains is plotted against the significance of the change. Each data point
represents one gene. Samsn1 is circled. (B) The reduced expression of Samsn1 in C57BL/KaLwRij bones was confirmed in independent
samples by real-time PCR (n = 4 per group) and Western blot. ****P b .0001, t test. (C) RNA was isolated from C57BL/KaLwRij (n = 3) and
C57BL/6 (n= 3) derived tissues and Samsn1mRNA expression was assessed by real-time PCR. (D) Cells were isolated fromC57BL/KaLwRij
(n=3) and C57BL/6 (n=3) BM (PCs and stromal cells) and peripheral blood (other cell subsets). Samsn1mRNAexpressionwas assessed by
real-time PCR. (E) 5TGM1 cells express negligible Samsn1, as determined by real-time PCR. C57BL/KaLwRij and C57BL/6 mouse PCs are
shown for comparison. ****P b .0001; ***P b .001; **P b .01; t test.
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greatly between patients [5].
Patients with MM can be stratified into various subgroups based
on the presence of defined genetic abnormalities in their malignant
PCs [6]. These genetic abnormalities include, but are not limited to,
del(13) [7], del(16q) [8], del(17p) [9], gain of 1q21 [10], as well as
translocations involving the immunoglobulin heavy chain locus, i.e., t
(4;14)(p16.3;q32) and t(14:16)(q32;q23) [11,12], all of which are
associated with poor prognosis. While these abnormalities arebelieved to play a major causative role in disease development,
studies suggest that many of them are already present in the clonal
PCs of patients with MGUS [13,14]. Therefore, it is likely that
additional, as yet undefined, factors are required for the progression
from asymptomatic MGUS to overt malignant MM. To this end,
recent studies suggest that changes in gene expression, including up-
regulation and/or down-regulation of key genes, which occurs through
epigenetic mechanisms, may play a key role in the development of
symptomatic MM [15].
Table 1.Genes Differentially Expressed in the Long Bones of C57BL/KaLwRij and C57BL/6 Mice
Symbol Definition Fold change Direction
Gbp1 Guanylate binding protein 1 4.450412306 Increase
Ddit4 DNA damage–inducible transcript 4 4.240428329 Increase
Hist4h4 Histone cluster 4, H4 3.37437661 Increase
Tmod4 Tropomodulin 4 3.353338216 Increase
Angptl7 Angiopoietin-like 7 3.283043806 Increase
Mx2 Myxovirus (influenza virus) resistance 2 3.249176241 Increase
Lyplal1 Lysophospholipase-like 1 3.139500408 Increase
Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 3.030790225 Increase
Pttg1 Pituitary tumor–transforming 1 2.94256646 Increase
Oas2 2′-5′ oligoadenylate synthetase 2 2.731815404 Increase
Oas1g 2′-5′ oligoadenylate synthetase 1G 2.704346478 Increase
Usp18 Ubiquitin specific peptidase 18 2.538251457 Increase
Ifi27l2a Interferon, alpha-inducible protein 27 2.533970976 Increase
Gbp7 Guanylate binding protein 7 2.508261909 Increase
Pisd-ps3 Phosphatidylserine decarboxylase, pseudogene 3 2.436705673 Increase
Per1 Period homolog 1 (Drosophila) 2.397020089 Increase
Sct Secretin 2.384120243 Increase
Irf7 Interferon regulatory factor 7 2.378730781 Increase
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 2.346674916 Increase
Rtp4 Receptor transporter protein 4 2.337282308 Increase
Oasl2 2′-5′ oligoadenylate synthetase-like 2 2.242105245 Increase
Msc Musculin 2.210238416 Increase
Hist1h4b Histone cluster 1, H4b 2.207251464 Increase
Igh-VJ558 PREDICTED: immunoglobulin heavy chain (J558 family) 2.193584071 Increase
Rbp7 Retinol binding protein 7, cellular 2.191502007 Increase
Pydc4 Pyrin domain containing 4 2.187228581 Increase
Npy Neuropeptide Y 2.170017985 Increase
Erdr1 Erythroid differentiation regulator 1 2.158546243 Increase
Thsd4 Thrombospondin, type I, domain containing 4,
transcript variant 1
2.133757168 Increase
Bfsp2 Beaded filament structural protein 2, phakinin 2.110095069 Increase
Paip1 Polyadenylate binding protein-interacting protein 1,
transcript variant 1
2.098810627 Increase
Cyr61 Cysteine rich protein 61 2.036144571 Increase
Mgst1 Microsomal glutathione S-transferase 1 57.60499461 Decrease
Samsn1 SAM domain, SH3 domain and nuclear localization signals, 1 51.76062024 Decrease
Entpd4 Ectonucleoside triphosphate diphosphohydrolase 4 19.42186718 Decrease
Slc25a37 Solute carrier family 25, member 37 16.9916612 Decrease
Slc22a4 Solute carrier family 22 (organic cation transporter),
member 4
14.15791584 Decrease
H2afj H2A histone family, member J 11.74400026 Decrease
Sparc Secreted acidic cysteine rich glycoprotein 9.001990237 Decrease
Bbs4 Bardet-Biedl syndrome 4 (human) 3.525644472 Decrease
Kif3a Kinesin family member 3A 3.134149503 Decrease
Tipin Timeless interacting protein 2.959086767 Decrease
Cdkn1b Cyclin-dependent kinase inhibitor 1B 2.908346173 Decrease
Vsig4 V-set and immunoglobulin domain containing 4 2.825793418 Decrease
Hist1h3f Histone cluster 1, H3f 2.804314199 Decrease
Sfrp4 Secreted frizzled-related protein 4 2.725447254 Decrease
Rps3a Ribosomal protein S3a 2.493150544 Decrease
Pml Promyelocytic leukemia (Pml), transcript variant 1 2.333694965 Decrease
Hist1h4i Histone cluster 1, H4i 2.240988119 Decrease
Dcp1b DCP1 decapping enzyme homolog b (S. cerevisiae) 2.233498058 Decrease
Aoah Acyloxyacyl hydrolase 2.202379368 Decrease
Adpgk ADP-dependent glucokinase 2.172734661 Decrease
Trim2 Tripartite motif protein 2 2.151279536 Decrease
Hdgf Hepatoma-derived growth factor 2.128178262 Decrease
Hist1h4f Histone cluster 1, H4f 2.085821933 Decrease
Plac9 Placenta specific 9 2.038744521 Decrease
Tbc1d9b TBC1 domain family, member 9B 2.012406842 Decrease
Arhgap26 Rho GTPase activating protein 26 2.005116414 Decrease
Expression in C57BL/KaLwRij bone relative to expression in C57BL/6 bone.
574 SAMSN1 is a myeloma tumor suppressor Noll et al. Neoplasia Vol. 16, No. 7, 2014In the present study, we used gene expression arrays to identify
transcriptomic differences between the closely related C57BL/KaLwRij
and C57BL/6 mouse strains that could account for the age-dependent
predisposition of C57BL/KaLwRij mice to develop a MM-like disease
[16,17]. From these analyses, Samsn1 was identified as one of the most
significantly downregulated genes in the C57BL/KaLwRij mousestrain. Further analysis revealed that the loss of Samsn1 expression was
due to a homozygous gene deletion encompassing the entire Samsn1
coding region in the C57BL/KaLwRij mouse.
SAMSN1 (also known as HACS1, SLY2, and SASH2) encodes a
member of the SLY family of cytoplasmic adaptor proteins and is
predominantly expressed in the hematopoietic compartment, with
lower levels of expression in heart, brain, placenta, and lung [18].
Studies in Samsn1 knockout mice, which are viable and fertile,
indicate that it may act to moderate adaptive immune responses [19].
Samsn1 has also been shown to play a role in B cell activation and
differentiation [20] and has been implicated as a tumor suppressor
gene in lung cancer [21]. However, to date, the precise cellular role of
SAMSN1 remains poorly understood.
In this study, we also show that SAMSN1 expression is low or
absent in a proportion of human myeloma cell lines (HMCLs) and
MM patient–derived PCs compared to PCs isolated from patients
with MGUS and healthy controls. Furthermore, we show that
methylation of the SAMSN1 promoter is a likely mechanism of
reduced SAMSN1 expression in human MM cells. Importantly,
overexpression of Samsn1 in the murine MM cell line, 5TGM1,
completely inhibited MM disease development in vivo and reduced
proliferation in stromal cell–PC co-cultures in vitro, suggesting that
SAMSN1 may function as a tumor suppressor in MM.Materials and Methods
Gene Expression Profiling by Microarray
Femora and tibiae from age- and sex-matched C57BL/6 and
C57BL/KaLwRij mice were extracted, cleaned thoroughly, and
snap-frozen in liquid nitrogen. Frozen bones were pulverized under liquid
nitrogen in a mortar and pestle, and RNA was extracted using the high salt
method [22]. Briefly, bone powder was homogenized in 4 M guanidinium
thiocyanate containing 0.5% sarcosyl and 4.5 mM 2-mercaptoethanol
by drawing repeatedly through a 19 G needle. Debris was removed
by centrifugation and RNA was separated from proteins and DNA using
acidified phenol/chloroform. Salt was removed by isopropanol precipitation
andwashingwith 70%ethanol. The extractedRNAwas further purified using
a silica gel-based membrane column (Qiagen RNeasy kit; Qiagen, Valencia,
CA). RNA was submitted to the Australian Genome Research Facility
(Parkville, Australia) for labeling and array hybridization to the IlluminaMouse
WG-6 v2.0BeadChip.Data analysiswas performed at theAustralianGenome
Research Facility. Four biologic replicates of each mouse strain were analyzed.Real-Time Polymerase Chain Reaction
Total RNA was isolated using TRIzol reagent (Life Technologies,
Carlsbad, CA) unless otherwise specified. RNAwas reverse transcribed using
Superscript III (Life Technologies) or Sensiscript (Qiagen) as per the
manufacturers’ instructions. Real-time polymerase chain reaction (PCR) was
conducted on a Rotor-Gene 3000 (Corbett Research, Mortlake, Australia)
using the following primers: mouse/human Actb (F: 5′-TTGCTGACAG-
GATGCAGAAG-3′ and R: 5′-AAGGGTGTAAAACGCAGCTC-3′),
mouse Samsn1 (F: 5′-TGCCTGCTCTCAGTTGTCTC-3′ and R: 5′-
TCCGAAAACGGTCAAAATTC-3′), human B2M (F: 5′-AGGCTATC
CAGCGTACTCCA-3′ and R: 5′-CGGCAGGCATACTCATCTTT-
3′), and human SAMSN1 (F: 5′-TCCCTCAAAGCCAGTGACTC-3′
and R: 5′-GCCACAGAATGGTCCTGAAT-3′). Changes in gene
expression were calculated relative to β-actin or β2-microglobulin using the
ΔΔCt method [23].
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Figure 2. The Samsn1 gene is deleted in C57BL/KaLwRij mice. (A) Extent of genomic deletion of the Samsn1 gene in C57BL/KaLwRij mice.
The two predominant protein coding isoforms from ensembl.org Mouse Genome Assembly are shown [Samsn1-001
(ENSMUST00000114240) and Samsn-003 (ENSMUST00000114239)]. Solid and open rectangles represent coding and non-coding
exons, respectively. The large hatched horizontal rectangle at the bottom represents the genomic interval that is deleted, with the letters
indicating the location of deleted (B–D) versus non-deleted (A and E) PCR primer binding sites. (B) PCR analysis of genomic DNA isolated
fromC57BL6 andC57BL/KaLwRij tissues/cell lines. Examplesof PCRs that detect regions that are present (A andE) or deleted (B–D) inC57BL/KaLwRij
tissues/cell lines are shown. The PCR primer names on the right-hand side correspond to those in Supplementary Table S1. NTC, no template
(negative) control. (C) Breakpoint PCR with primer BP1F/DEL+55kb.F is only detectable in C57BL/KaLwRij-derived tissues or cell lines.
The position of the breakpoint is indicated by the change from emboldened to normal text above the sequence chromatogram.
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Approximately 500 μl of peripheral blood was obtained from mice
by cardiac puncture and collected in microfuge tubes containing 50
μl of 0.5 M EDTA. Femora and tibiae were flushed and BM cells
were collected. Red blood cells were removed by hypotonic lysis and
leukocytes were stained with phycoerythrin (PE)-Cy7–conjugated rat
anti-mouse B220 (eBioscience, San Diego, CA), fluorescein
isothiocyanate–conjugated rat anti-mouse CD3 (eBioscience), PE-
Cy5–conjugated rat anti-mouse CD11b (BioLegend, San Diego,
CA), APC-conjugated rat anti-mouse Gr1 (eBioscience), and PE-
conjugated rat anti-mouse NK1.1 (BD Biosciences, San Jose, CA).
FluoroGold (Life Technologies) was used to exclude dead cells. Cells
were sorted on a FACSAria II (BD Biosciences) into B cell (B220+), T
cell (CD3+NK1.1−), monocyte (CD11bhiGr1lo), and granulocyte
(CD11bhiGr1hi) populations for RNA extraction and real-time PCR.
PCs were isolated from flushed long bones and identified using ratanti-mouse CD138 (R&D Systems, Minneapolis, MN) followed by
PE-conjugated goat anti-rat IgG.
Deletion Mapping
Genomic DNA was isolated from mouse tissues using the DNeasy
Blood and Tissue Kit (Qiagen) and PCRs were performed using
AmpliTaq Gold Taq DNA Polymerase (Applied Biosystems, Foster
City, CA), in accordance with the manufacturers’ recommendations.
Primers and annealing temperatures are indicated in Supplementary
Table S1. PCR products spanning the breakpoint were cloned into
pGEMT-Easy vector (Promega, Madison, WI) before sequencing.
Patient Samples
BM trephines were collected, with informed consent, from patients
with MM or MGUS and from hematologically normal controls. All
MM samples were collected from patients at diagnosis with no prior
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Figure 3. SAMSN1 expression is reduced in CD138+ PCs of patients with MM and HMCL. (A) SAMSN1 expression (as determined by
real-time PCR) is significantly reduced in the BMs of patients with MM (n = 34) compared with patients with MGUS (n = 9) and healthy
age-matched controls (n = 5; *P b .05, **P b .001, one-way ANOVA with Tukey’s multiple comparison test). (B) SAMSN1 expression in
CD138+MACS isolated PCs from patients withMMnegatively correlates with BMPC burden (n=10, r2 = 0.6147, P= .0043). (C) In silico
analysis of published microarray data. CD138+ PCs were isolated by MACS from 414 patients with MM, 44 patients with MGUS, and 22
age-matched controls. RNA was extracted and analyzed using the Affymetrix U133Plus2.0 microarray platform (GEO Accession Nos
GSE4581 and GSE5900). Expression of SAMSN1 is significantly reduced in PCs of patients with MM compared to those of patients with
MGUS and normal controls. P b 0.0001, one-way ANOVA with Tukey’s multiple comparison test. (D) Total RNA was extracted from six
HMCLs and reverse transcribed. The levels of SAMSN1 expression were assessed by real-time PCR.
576 SAMSN1 is a myeloma tumor suppressor Noll et al. Neoplasia Vol. 16, No. 7, 2014therapy. This study was approved by the Royal Adelaide Hospital
Human Research Ethics Committee.
CD138+ Magnetic-Activated Cell Sorting and
RNA/DNA Isolation
CD138+ PCs were isolated from human BM samples from
patients with MM (at diagnosis) using CD138 microbeads (Miltenyi
Biotec, Auburn, CA) as per the manufacturer’s instructions. Briefly,
cryopreserved human BM samples (approximately 107 cells/ml)
were thawed into 10 ml of Dulbecco's modified Eagle's medium
(high glucose) with 15% fetal calf serum (FCS) and DNase. Sample
was centrifuged at 300g for 10 minutes and the supernatant was
aspirated. Cell pellet was resuspended in magnetic-activated cell
sorting (MACS) buffer (2mM EDTA and 0.5% deionized BSA in
phosphate-buffered saline) and CD138 microbeads were added.Cells/beads were incubated on ice for 15 minutes, washed in 1 ml of
MACS buffer, and centrifuged at 300g for 10 minutes. Cells were
resuspended in MACS buffer and applied to a pre-rinsed MS column.
The columnwas washed three times withMACS buffer, followed by elution
in 1ml. The purity of final elution was determined by FACS analysis using a
CD138-PE antibody and samples were confirmed to be N85% CD138+
following MACS. Total RNA and DNA were subsequently isolated
using an All Prep DNA/RNA Micro Kit (Qiagen).
Cell Culture
Mouse 5TGM1 myeloma cells were maintained in Iscove’s
modified Dulbecco’s medium (Sigma, St Louis, MO) with
20% FCS. HMCLs were maintained in RPMI-1640 medium
(Sigma) with 10% FCS. BM stromal cells (BMSCs) were maintained
inα-minimum essential medium (Sigma) with 10% FCS and 100 mM
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Figure 4. TheSAMSN1gene ismethylated inHMCLs. (A)H929,U266, LP-1, andJIMIcellswere treatedwith500nM5-aza-2′-deoxycytidine for 96
hours. Total RNA was isolated from treated and untreated controls. SAMSN1 expression was significantly increased in response to 5-aza-2′-
deoxycytidine treatment in the H929 and U266 cell lines, as determined by real-time PCR. *P b .05, t test. (B) SAMSN1 promoter methylation in
HMCLs. Patterns of CpG methylation revealed by sequencing of cloned PCR products for the two promoters of SAMSN1 are shown. Closed
circles represent methylated CpGs and open circles represent unmethylated CpGs. The HMCLs are grouped according to SAMSN1 expression
levels. The−470/−460 CpGs whose methylation status correlates with expression level are highlighted by the vertical hatched rectangle. The
numbers above theCpGs are relative to the transcription start sites of the SAMSN1-001 (ENST00000285670) isoform for the upstreampromoter
and the SAMSN1-002 (ENST00000400566) and SAMSN1-002 (ENST00000400564) isoforms for the downstream promoter. SAMSN1 isoform
data are from ensembl.org Human Genome Assembly GRCh37.p13.
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2mML-glutamine, 100U/ml penicillin, 100μg/ml streptomycin, 1mM
sodium pyruvate, and 10 mM Hepes buffer (Life Technologies).
Methylation Analysis
Genomic DNA from myeloma cell lines was isolated using the
DNeasy Blood and Tissue Kit (Qiagen). Two micrograms of DNA
was bisulfite modified using the EpiTect Bisulfite Kit (Qiagen).
Modified DNA was PCR amplified using EpiMark Hot Start Taq
DNA Polymerase (New England Biolabs, Ipswich, MA) using
the following primers: for downstream promoter: SAMSN1.30mer.
F1 (5′-AGTTATGTTTTTATTTATATTTAGAATGGG-3′)
and Downstream.01.R (5′-TCACCCAAACTAAAATACAA
TAACA-3′); for upstream promoter: SAMSN1.BIS.F (5′-TTG
TTTTTATTTTGAGTTGTGTTTGT-3′) and SAMSN1.BIS.R
(5′-ACTAAACTTCCTCCATTACTCTCTCTC-3′). PCR prod-
ucts were subcloned into pGemT-Easy vector (Promega) before
sequencing. CpG methylation was assessed using QUMA (quma.cdb.
riken.jp/).
Generation of Samsn1-Overexpressing Cell Lines
A luciferase-expressing 5TGM1 cell line (as described previously
[24]) and an HMCL (H929)–overexpressing Samsn1 were generated
by infection with a retroviral vector (pRUFimCH2 or pRUFiG2,
respectively) harboring a full-length cDNA encoding murine or
human Samsn1. pRUFiG2 was generated from pRUFneo [25].
Briefly, oligonucleotides encoding NotI and loxp sequences were
cloned into the ClaI site at the 5′ end of the MC1Neo gene. An
oligonucleotide encoding an loxp sequence and a new multiple
cloning site (including BamHI, HpaI, EcoRI, BglII, SacII, SnaBI,
NdeI, and XhoI) was cloned into the BamHI site of pRUFneo. The
MC1Neo gene was excised and replaced with an internal ribosome
entry site, green fluorescent protein (IRES-GFP) cassette from
pMSCV-IRES-GFP to generate pRUFiG2. To generate pRU-
FimCH2, the IRES-GFP cassette was excised from pRUFiG2 with
XhoI and NotI and replaced with the IRES-mCherry cassette from
pcDNA3-IRES-mCherry.
The full-length murine Samsn1 cDNA was PCR amplified from a
Mus musculus Samsn1 cDNA clone (clone 30077237; Open
Biosystems, Huntsville, AL) and subcloned into pRUFimCH2
to generate pRUFimCH2-Samsn1. The full-length human
SAMSN1 cDNA was PCR amplified from a Homo sapiens
SAMSN1 cDNA clone (clone 4343284; Open Biosystems) and
subcloned into pRUF-iG2 to generate pRUF-iG2-SAMSN1. Retro-
viral vectors were transfected into HEK-293T cells and viral particle-
containing supernatant was used to infect 5TGM1-luc cells or H929
cells, as previously described [26]. Cell lines were sorted on a
Beckman Coulter Epics Altra HyperSort, using Expo MultiComp
Software version 1.2B (Beckman Coulter, Miami, FL) and pooled cellFigure 5. Overexpression of Samsn1 completely inhibits MM tumor
5TGM1-Samsn1 cells. (B) No significant difference was seen in the pro
by BrdU incorporation. (C) C57BL/KaLwRij mice were injected intraven
intraperitoneally and tumor growth was assessed using the Xenogen IV
control (upper panel) and Samsn1-expressing (lower panel) 5TGM1 cells
5TGM1cells is significantly reducedcompared to control cells as determin
(D) Representative three-dimensional images of the tibial trabecular struc
carrying 5TGM1-Samsn1 tumors as determined by bone volumeanalysis
of the tibial cortical structure of tumor-bearing mice. There was no signilines were established from the top 30% of mCherry or GFP-expressing
cells. Resultant Samsn1-overexpressing cell lines (and empty vector
controls) were used for subsequent in vitro and in vivo assays.
Western Blot
5TGM1 cells (2 × 107) were lysed in 1 ml of lysis buffer containing
1% NP-40, 20 mM Hepes, 150 mM NaCl, 10% glycerol, 2 mM
Na3VO4, 10 mM Na4P2O7, 2 mM NaF, and Complete EDTA-free
Protease Inhibitor Cocktail (Roche, Mannheim, Germany). One
hundred micrograms of lysate was loaded on a 10% acrylamide gel
and subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Proteins were transferred to polyvinylidene difluoride
membrane overnight and the membrane was subsequently incubated
at room temperature in blocking buffer [Tris-buffered saline
containing 0.1% Tween 20 and 2.5% ECL Blocking Agent (GE
Healthcare, Little Chalfont, United Kingdom)] for 6 hours. The
membrane was incubated overnight at 4°C with rabbit polyclonal
anti-SAMSN1 antibody (Sigma) diluted 1:500 in blocking buffer,
followed by alkaline phosphate-conjugated anti-rabbit IgG (Millipore,
Billerica, MA) diluted 1:2500 in blocking buffer for 1 hour at room
temperature. Proteins were visualized using ECL detection reagent (GE
Healthcare) on a Typhoon FLA 7000 IP2 (GE Healthcare).
5-Aza-2′-Deoxycytidine Treatment in HMCL
HMCLs were seeded at 2 × 105 cells/ml and treated with 500 nM
5-aza-2′-deoxycytidine (Life Technologies) diluted in culture medi-
um for 96 hours, replenishing treatment media daily. Total RNA was
isolated from treated cells and untreated controls and specific gene
expression was determined by real-time PCR.
Adhesion Assays
BMSCs were seeded at 8 × 103 cells per well in a 96-well plate and
allowed to adhere overnight. Empty wells (plastic) were used as controls
for adhesion. H929 or 5TGM1 cells (expressing an empty vector
control or SAMSN1) were seeded at 2 × 104 cells per well in 100-μl
volume and incubated for 10minutes at 37˚Cwith 5%CO2. Cells were
gently aspirated followed by three washes with 100 μl of HBSSwith 5%
FCS to remove non-adherent cells. One hundred microliters of
standard culture medium was added to each well and four images taken
per well at ×10 magnification. The number of GFP-positive cells per
field of view was determined using FIJI analysis software (http://fiji.sc).
Proliferation Assays
5TGM1 cells were seeded at 2000 cells per well in triplicate in a
96-well plate. BrdU (Roche) was added to the cells and incubated for
24 hours at 37˚C with 5% CO2. Cells were fixed and stained as per
the manufacturer’s protocol and absorbance was measured at 450 nm.
BMSCs were seeded at 5 × 104 cells per well in a 96-well plate (black
plate with clear, flat bottom; Corning Life Science, Pittston, PA) in 100growth in vivo. (A) Western blot for Samsn1 in 5TGM1-vector and
liferation of 5TGM1-vector and 5TGM1-Samsn1 cells as determined
ously with 5 × 105 5TGM1 cells. On day 28, mice received luciferin
IS 100. Bioluminescence images of tumor growth in mice receiving
(n= 5 per group) are shown. The in vivo growth of Samsn1-expressing
edbyquantificationof photon flux. **P=.0079,Mann-WhitneyU test.
ture of tumor-bearing mice. Osteolysis was significantly lower in mice
(*P= .0244, t test,n=5). (E) Representative three-dimensional images
ficant difference in the number of cortical pits.
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adhere overnight. The medium was aspirated and 5TGM1-Samsn1 or
5TGM1-vector cells were seeded (in triplicate) at 5 × 103 cells per well
in 100 μl of Iscove’s modifiedDulbecco’s media + 20%FCS. Cells were
incubated for 3 days at 37˚C with 5% CO2. Bioluminescence was
determined using the Xenogen IVIS 100 Bioluminescence Imaging
System (Caliper Life Sciences, Hopkinton, MA), following addition of
100 μl of 300 ng/ml luciferin per well and analysis using Living Image
software (PerkinElmer, Waltham, MA). Absolute cell number per well
was determined using a standard curve for bioluminescence.
Animals
C57BL/6 and C57BL/KaLwRij mice were bred and housed at the
Institute of Medical and Veterinary Science Animal Care Facility.
Animal studies were approved by the Institute of Medical and
Veterinary Science/Adelaide Health Service and University of
Adelaide Animal Ethics Committees. C57BL/KaLwRij mice (aged
6-8 weeks) received 5 × 105 luciferase-expressing 5TGM1 cells in 100
μl of sterile phosphate-buffered saline through the tail vein. At weekly
intervals, mice were administered 150 mg/kg luciferin intraperitoneally
and imaged using the Xenogen IVIS 100 Bioluminescence Imaging
System until termination of the experiment at day 28. Tumor burden
was quantitated using Living Image software.
μ-CT Analysis
Bone volume was evaluated using μ-CT (Skyscan 1174 X-ray
Microtomograph; BrukerMicroCT, Kontich, Belgium). All tibiae were
scanned at 48 kV/800 μA, with an isometric resolution of 6.49 μm/
pixel using a 0.25-mm aluminium filter and two-frame averaging.
Reconstruction of the original scan data was performed using NRecon.
Analysis of bone volume fraction (BV/TV) was performed using CTAn.
A total of 300 slices (1.947 mm) was analyzed for each tibia,
commencing 85 slices (0.552 mm) distal to the growth plate. Digital
segmentation of the bone from air/tissues was performed by adaptive
(median-C) thresholding. The volume of interest were reconstructed in
three dimensions using ANT software.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.02
for Windows (GraphPad Software, San Diego, CA; www.graphpad.
com). Variance between patient groups was compared using analysis of
variance (ANOVA) with Tukey’s multiple comparison test. Differences
in tumor burden were compared between groups using a Mann-
Whitney U test. In vitro assays were analyzed using t tests or ANOVA
as appropriate. A P value of .05 was considered statistically significant.Results
Samsn1 Expression Is Significantly Reduced in
C57BL/KaLwRij Mice
To identify factors that may contribute to the development of
MM, we compared the gene expression profiles from the closely
related C57BL/6 and C57BL/KaLwRij mouse strains. While both the
C57BL/6 and C57BL/KaLwRij strains have been demonstrated to
develop monoclonal gammopathy at a similar rate (60-70% by 2 years
old) [27,28], the C57BL/KaLwRij mice are unique in their ability to
spontaneously develop MM at a low frequency (0.5% of mice N 2 years
old). Furthermore, the C57BL/KaLwRij strain allows the successful
engraftment of exogenous murine myeloma PCs, while the C57BL/6strain does not [16,17,29]. The C57BL/KaLwRij model is one of the
most widely studied preclinical animal models of MM and the MM
disease exhibited by these animals faithfully recapitulates the symptoms
of the human disease, including osteolysis [16,30–32]. In addition, these
animals have previously been used to identify factors that play a role in
the pathogenesis of human MM [33,34].
Total RNA was extracted from the long bones (tibiae and femora)
of age- and sex-matched C57BL/6 and C57BL/KaLwRij mice.
Expression profiling of the long bones revealed a small number of
genes (87) that are differentially expressed between the two strains by
two-fold or more (Figure 1A). Of these, 22 were unnamed genes with
no identified function and a further 7 had no human orthologue.
Literature searches were conducted for the remaining 58 genes
(Table 1) and these were subsequently prioritized for further
investigation based on their potential relevance to MM. Statistically
significant differences in expression were confirmed by quantitative
PCR for 5 of the 20 most promising candidates (data not shown). Of
particular interest was the expression of Samsn1, which was shown to
be absent in the bone of C57BL/KaLwRij mice at both the mRNA
and protein levels (Figure 1B). Samsn1 has been shown to play a role
in regulating adaptive immune responses and the development of B
cells [19,20], which, coupled with our microarray data, highlighted
Samsn1 as a promising candidate for further investigation into its
potential role in the development of MM.
Loss of SAMSN1 Is a Feature of the 5TGM1/C57BL/KaLwRij
Mouse Model of MM
To identify whether Samsn1 may play a role in the development of
MM in the mouse model, we first investigated Samsn1 mRNA
expression in various tissues and found it to be consistently absent
within the C57BL/KaLwRij mice compared to C57BL/6 controls
(Figure 1C). Previous studies have shown that Samsn1 is expressed in
cells of the hematopoietic compartment [18]. As such, hematopoietic
cell subsets (B cells, T cells, monocytes, granulocytes, PCs, and
stromal cells) were isolated by FACS and Samsn1 expression was
evaluated by real-time PCR. As seen in Figure 1D, Samsn1 mRNA
expression was absent across the entire range of hematopoietic cell
subsets, including PCs, the effector cells of MM. Notably, this lack of
Samsn1 expression was also evident in the well-characterized 5TGM1
cell line (Figure 1E), a finding consistent with its C57BL/KaLwRij
origin. From these findings, we hypothesized that the absence of
Samsn1 expression in these mice, and specifically within the
malignant 5TGM1 PCs, may represent a crucial mechanism by
which MM disease develops in this murine model.
The Samsn1 Gene Is Deleted in C57BL/KaLwRij Mice and
5TGM1 Murine PCs
To identify a mechanism for the global lack of Samsn1 expression
in the C57BL/KaLwRij mice, we attempted to PCR amplify the two
promoter regions of Samsn1 to analyze this region for CpG
methylation (see Figure 2A for overview of the gene structure).
Interestingly, using primers designed specifically to the downstream
promoter region of the Samsn1 gene, we were unable to amplify the
genomic DNA from tissues derived from the C57BL/KaLwRij mice
(data not shown). Upon further analysis, we identified a large
chromosomal deletion, encompassing the entire coding region of the
Samsn1 gene in the C57BL/KaLwRij mice. Notably, the correspond-
ing region in the C57BL/6 control strain was not deleted (Figure 2B,
Supplementary Table S1, Supplementary Figure S1). PCR performed
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Figure 6. Overexpression of Samsn1 increases adhesion and decreases cell growth on stroma in vitro. (A) 5TGM1-Samsn1 or -vector
control cells were allowed to adhere to a monolayer of BMSCs for 10 minutes, followed by gentle washing to remove non-adherent cells.
The number of GFP+ adherent cells was determined using FIJI analysis software. Mean ± SEM, n = 4, ***P b .001, t test. (B) Equal
numbers of 5TGM1-Samsn1 or -vector control cells were seeded on BMSC and the total number of cells after 72 hours was determined
by bioluminescence imaging techniques. Mean ± SEM, n = 3, *P b. 05, paired t test.
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interval (Figure 2A), only yielded a product with KaLwRij-derived
genomic DNA (Figure 2C). Sequencing of this PCR product revealed
that the deletion is 179,971 bp in length and extends from midway
through intron 2 to an intergenic region between Samsn1 and the
next nearest downstream gene, Hspa13. The deleted region extends
from 75,816,191 to 75,996,161 of mouse chromosome 16, and the
three genes Hspa13, Rbm11, and Lipi that are located immediately
downstream of Samsn1 were not deleted (data not shown;
Supplementary Table S1). Notably, the 179,971 bp deletion was
also shown to be present in the 5TGM1malignant PC line (Figure 2, B
and C). These data indicate that the C57BL/KaLwRij mice are
genetically null for Samsn1. This model of MM therefore does not
express Samsn1 in the microenvironment or in the malignant PCs and
therefore provides an ideal model through which to investigate the role
of PC-specific Samsn1 expression in MM disease development in vivo.
Samsn1 Expression Is Reduced in a Subset of Patients
with MM
To ascertain whether SAMSN1 is also aberrantly expressed in
patients withMM, RNAwas extracted from total BM trephine biopsies
recovered from patients with MM (n = 34) and MGUS (n = 9)
at diagnosis and from hematologically normal, age-matched controls
(n = 5). SAMSN1 expression was shown to be significantly reduced inthe BMs of patients with MM when compared with those of patients
with MGUS and age-matched controls (P = .0019, one-way ANOVA;
Figure 3A).We next wanted to investigate the PC-specific expression of
SAMSN1 in patients with MM. Therefore, we specifically isolated
CD138+ PCs from BM samples of patients with MM using MACS
techniques and were subsequently able to determine that patients
presenting with higher BM PC burden at diagnosis had significantly
lower PC-specific SAMSN1 expression (n = 10, r2 = 0.6147, P = .0043;
Figure 3B). In support of our findings, in silico analyses of publicly
available data sets from large-scale microarray studies (GEO Accession
Nos GSE4581 and GSE5900; Myeloma Institute, University of
Arkansas) also showed that SAMSN1mRNA expression was significantly
reduced in purified PCs frompatients withMM(n = 414) comparedwith
patients with MGUS (n = 44) and healthy age-matched controls (n = 22;
P b .0001, one-way ANOVA; Figure 3C). Interrogation of these data sets
revealed that approximately 25% of patients with MM express SAMSN1
below the normal range compared to only 7% of patients with MGUS.
Low SAMSN1 expression was also observed in four of six HMCLs
examined (Figure 3D). Together, these data suggest that there is a
significant reduction in SAMSN1 expression in myeloma PC.
The Samsn1 Promoter Is Methylated in HMCLs
Despite its reduced expression levels in lung cancer cell lines [21],
methylation of the SAMSN1 promoter has not been previously
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due to the significant reduction of SAMSN1 expression in patients
with MM and HMCLs, SAMSN1 expression may be modulated by
differential methylation of the promoter. In support of this, a recent
study by Heller et al. listed SAMSN1 as a significantly upregulated
gene in two myeloma cell lines following treatment with the DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine [35]. Consistent
with these findings, we showed an increase in mRNA expression of
SAMSN1 in two HMCLs (U266 and H929) following treatment with
500 nM 5-aza-2′-deoxycytidine for 96 hours (Figure 4A). Interestingly,
although displaying similar low basal SAMSN1 expression levels, the
JIMI and LP-1 cell lines did not exhibit an increase in SAMSN1
expression following treatment with 5-aza-2′-deoxycytidine (Figure 4A).
To investigate this further, we examined the methylation pattern of
the SAMSN1 promoter region in a panel of HMCLs using bisulfite-
sequencing techniques. Similar to its mouse orthologue, the human
SAMSN1 gene has two promoter regions associated with the full-
length protein coding isoforms (see Figure 2A). As seen in Figure 4B
(left panel), there is evidence of high levels of methylation of the CpG
dinucleotides in the upstream SAMSN1 promoter region of all
HMCLs screened. In contrast, the downstream SAMSN1 promoter
exhibited differential methylation, particularly in the two central
CpGs at −470 and −460 relative to the transcription start site
(Figure 4B, right panel, hatched box). Importantly, the degree of
methylation of the −470 and −460 CpGs of the downstream
promoter corresponded with SAMSN1 expression levels in the
HMCLs, with the lowest levels of combined methylation of these two
CpGs seen in the RPMI-8226 (28%) and WL-2 (19%) cell lines,
which show the greatest expression of SAMSN1 (see Figure 3D). In
contrast, H929 (56%), U266 (100%), and LP-1 (100%) cells exhibit
higher degrees of methylation at the −470 and −460 CpGs and do
not express SAMSN1. Consistent with the lack of induction of
SAMSN1 expression following treatment with 5-aza-2′-deoxycyti-
dine, JIMI cells exhibit −470/−460 CpG methylation levels
equivalent to that seen in the RPMI-8226 and WL-2 cell lines
(5%). Interestingly, although displaying low basal SAMSN1
expression and a high degree of promoter methylation, the LP-1
cell line also did not respond to 5-aza-2′-deoxycytidine treatment.
These data suggest a role for promoter methylation in the modulation
of SAMSN1 expression and also highlight the existence of alternative,
yet to be defined, mechanisms.
Overexpression of Samsn1 in 5TGM1 Cells Completely Inhibits
MM Disease Development In Vivo
As detailed above, our studies show that Samsn1 expression is
absent in the 5TGM1/C57BL/KaLwRij mouse model of myeloma,
and this is consistent with reduced expression in a subset of patients
with MM. We next aimed to determine whether restoration of
Samsn1 expression in the 5TGM1 cells affects the development of
MM in vivo. Luciferase-expressing 5TGM1 cells (which do not
express Samsn1; see Figure 1E) were transduced with a Cherry-
labeled Samsn1 expression construct (5TGM1-Samsn1) or vector
control (5TGM1-vector), and Samsn1 expression was confirmed by
real-time PCR (data not shown) and Western blot (Figure 5A). The
expression of Samsn1 in 5TGM1-Samsn1 cells was equivalent to
levels seen in PC isolated from C57BL/6 mice (data not shown). The
use of luciferase-labeled cells allowed us to track the progression of
MM disease spread and development in vivo using bioluminescence
imaging techniques [24,34].Re-expression of Samsn1 in 5TGM1 cells had no effect on their
proliferative capacity in vitro, as determined by a BrdU incorporation
assay (Figure 5B). However, re-introduction of Samsn1 to the
5TGM1 cells was found to significantly inhibit the development of
MM disease in vivo, as seen by a significant decrease in
bioluminescence of 5TGM1-Samsn1–inoculated mice compared to
the 5TGM1-vector controls (P = .0079, Mann-Whitney U test;
Figure 5C). In keeping with the absence of tumor in mice inoculated
with 5TGM1-Samsn1 cells, the bone volume fraction in the tibiae of
these animals was significantly greater than that of control tumor-
bearing mice (32.18 ± 0.3815% compared with 30.38 ± 0.5256%, P =
.0244, two-tailed t test; Figure 5D). While the number of resorption
lacunae that traversed the cortices of the tibiae of both groups was
similar (63.8 ± 6.402 compared with 71.9 ± 3.519, P = .2998;
Figure 5E), the resorption lacunae in the 5TGM1-Samsn1 group
tended to be smaller. These data indicate that restoring expression of
Samsn1 in the murine 5TGM1 PCs can completely abolish the
capacity of these cells to form intramedullary tumors in vivo and
therefore prevents the osteolysis that is commonly observed in this
tumor model in response to MM.
SAMSN1 Overexpression Reduces Cell Growth in the Presence
of BMSCs In Vitro
To determine a mechanism by which Samsn1 expression may
inhibit the development of MM, we investigated the adhesive
properties of the vector- and Samsn1-expressing cells in vitro.
5TGM1-Samsn1 cells exhibited an increased capacity to adhere to a
BMSC layer compared to the 5TGM1-vector control cells in a short-
term in vitro adhesion assay (Figure 6A). This was confirmed in the
H929 HMCL (Supplementary Figure S2). As adherence of cells of
the hematopoietic lineage to stroma has previously been demonstrat-
ed to reduce proliferation [36–38], we next wanted to ascertain
whether this increase in adhesion was associated with an altered
proliferative capacity of the 5TGM1-Samsn1 cells. 5TGM1-Samsn1
and 5TGM1-vector cells were grown in the presence of BMSC and
total cell number was quantified after a 72-hour incubation period.
The total number of 5TGM1-Samsn1 cells was reduced compared
to the vector control cells (Figure 6B), suggesting that the expression
of Samsn1 in PCs may play a role in regulating cell adhesion and
proliferation, thereby accounting for the lack of tumor growth
observed in vivo.
Discussion
This is the first study to identify a key genetic variation, specifically the
deletion of the Samsn1 gene, in the C57BL/KaLwRij mice, which may
contribute to the propensity of these mice to spontaneously develop
myeloma-like disease. Moreover, analysis of patient data showed that
while expressed in PCs from healthy donors and patients with MGUS,
SAMSN1 expression is significantly reduced in patients with MM
suggesting a role for SAMSN1 in MM disease development and/or
progression. Furthermore, we also showed that restoration of Samsn1
expression in MM PCs inhibited myeloma disease development in vivo,
highlighting a potential tumor suppressor role for this protein in MM.
Although loss of heterozygosity at the chromosomal region 21q11-21,
which includes the SAMSN1 gene, has previously been associated with
lung cancer development [21], this is the first study in which SAMSN1
has been shown to play a tumor suppressor role in a hematological
malignancy. Interestingly, this chromosomal region has also been
identified as a region of frequent translocation events in hematological
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of chromosomal gain in a small number of patients with MM [40].
Furthermore, studies have previously shown an increase in SAMSN1
expression both in PC leukemia and MM [18,41]. The contradiction
between these studies and our own findings can likely be attributed to the
large degree of genetic heterogeneity observed in patients with MM.
Indeed, the study by Ni et al. identified a gain of 21q (specifically
associated with a gain of SAMSN1) in only a very small number of
patients on the background of a BCL1/JH t(11;14) (q13;q32)
translocation, while we observe significantly reduced SAMSN1 expression
in an unbiased sample of total BM trephines from patients with MM
compared to healthy donors. Furthermore, our findings are supported by
preliminary in silico analysis of the University of Arkansas gene expression
data set with approximately 25% of MM patient–derived PC expressing
SAMSN1 below the normal range. Further in silico analysis also suggests
that reduction of SAMSN1 is not associated with any particular MM
genetic subtype. Rather, patients with low SAMSN1 expression can be
found inmost subgroups. However, within each subgroup, these patients
tend to have poorer disease-related survival compared to patients with
SAMSN1 expression levels in the normal range (data not shown). This
is also consistent with the correlation observed between increased BMPC
burden and low CD138+ PC-specific SAMSN1 expression. It will be
important in the future to determine what common genetic anomalies
may be associated with reduced SAMSN1 expression in patients,
e.g., activated nuclear factor kappa B pathway signaling, deregulated
MYC, or common translocations, which may account for the
enhanced severity of disease. It will also be necessary to dissect out
whether these genetic signatures are the cause or consequence of
reduced SAMSN1 expression.
Although Yamada et al. demonstrated frequent down-regulation of
SAMSN1 in lung cancer cell lines, no mechanism for this down-
regulation was identified [21]. A number of recent studies have shown
global hypomethylation of the genome to be associated with the
progression of MM disease from the non-malignant MGUS stage, with
the majority of this hypomethylation occurring outside of defined CpG
islands [15,42,43]. Gene-specific hypermethylation, associated with
CpG islands within promoter regions, is also evident in MM
progression. This hypermethylation has, to date, largely been associated
with genes involved in developmental processes, cell cycle, and
regulation of transcription [15,43]. In this study, we present SAMSN1
as a novel gene exhibiting hypermethylation in cell lines derived from
patients with MM. We have correlated differential methylation of
specific CpGs within the downstream SAMSN1 promoter with gene
expression levels. Furthermore, we demonstrated an increase in
SAMSN1 expression in HMCLs following treatment with the DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine. This is supported
by a previous study showing a significant increase in SAMSN1
expression in an HMCL upon treatment with 5-aza-2′-deoxycytidine
[35]. This finding provides evidence of SAMSN1 hypermethylation
and subsequent down-regulation as a potential marker of MM disease.
C57BL/KaLwRij and C57BL/6 are closely related strains of mice.
The C57BL/KaLwRij strain uniquely exhibits an inherent ability to
develop MM disease as well as permitting the growth of the
exogenous 5T series of mouse MM lines, while the C57BL/6 strain
does not [16,17,29]. The 5TGM/C57BL/KaLwRij model provided
an ideal opportunity to investigate the effect of PC-specific Samsn1
expression on the in vivo development of MM, as we have shown a
large genomic deletion within chromosome 16, encompassing the
entire Samsn1 coding region, resulting in an animal that is null forSamsn1 expression. As this deletion was shown to be specific to the
C57BL/KaLwRij strain, we hypothesized that the deletion of Samsn1
was necessary but not sufficient for the unique development of MM
in these animals. Despite being Samsn1 null, C57BL/KaLwRij mice
only develop MM at a very low rate (approximately 0.5% greater than
2 years old) [16], suggesting that the loss of Samsn1 alone is not
sufficient to drive the development of this disease. It is therefore likely
that the 5TGM1 cells contain further genetic or epigenetic alterations
that, in combination with the loss of Samsn1, account for the
malignancy in this system.
It is evident that the PC-specific loss of Samsn1 expression is
critical in the development of MM, as restoration of Samsn1
expression in the 5TGM1 cell line significantly inhibited disease
development in vivo. In keeping with this finding, SAMSN1
expression is significantly reduced both in a subset of HMCLs and
within CD138+ purified PCs from BMs of patients with MM.
Together, these data suggest that the role of SAMSN1 in MM
development is likely to be largely PC-specific.
Although the precise cellular function of SAMSN1 is largely
unknown, it has been reported to be expressed primarily in the
hematopoietic compartment [18] and to be up-regulated by B cell
stimulators resulting in the activation and differentiation of B cells
[20]. In addition, overexpression of Samsn1 in murine splenic B cells
resulted in inhibition of proliferation, while mice with knock-out
Samsn1 showed increased proliferation of naïve B cells [19,20].
Collectively, these data support a role for SAMSN1 in B cell
development and function. In addition, a role for SAMSN1 in actin
cytoskeleton organization and B cell spreading has also been proposed
[44]. Our preliminary findings suggest that expression of SAMSN1 in
myeloma cell lines results in increased adhesion to BMSCs and
subsequent decreased cell growth in short-term in vitro assays,
accounting for the reduced tumor growth observed in vivo. This is in
contrast to cells grown in the absence of BMSC wherein no change in
proliferation is observed. These findings are supported by previous
studies that have demonstrated a link between increased adhesion of
hematopoietic progenitor cells to stroma and decreased cellular
proliferation [36,37]. In addition, specific binding of hematopoietic
progenitor cells through the cell adhesion molecule PSGL-1 has been
associated with suppressed cellular proliferation [45] and adhesion of
lymphoma cells to BMSCs results in G1 arrest [38]. Taken together,
these data implicate SAMSN1 as not only a modulator of B cell
development and function [19,20,44] but also a protein that plays a
role in controlling cell adhesion and proliferation of PCs within the
BM microenvironment. However, it remains to be fully elucidated as
to how loss of SAMSN1 contributes to MM development and this
requires further investigation.
The structural nature of SAMSN1, specifically the presence of SH3
and SAM domains, places it in the class of intracellular adaptor
molecules [46,47]. Therefore, it is probable that key interactions and
signaling pathways are modulated through SAMSN1 and the
deregulation of these pathways contributes to the development of
MM. Further investigation is required to identify a mechanism of
action for SAMSN1 in suppressing MM tumor development,
including potentially important interacting partners and downstream
activated and/or repressed pathways.
Conclusions
In summary, we have identified Samsn1 as anMM tumor suppressor gene
with reduced SAMSN1 expression observed both in the C57BL/KaLwRij
584 SAMSN1 is a myeloma tumor suppressor Noll et al. Neoplasia Vol. 16, No. 7, 2014mouse model of MM and a proportion of patients with MM. Further
studies of the prognostic significance of reduced SAMSN1 expression in
patients with MM are warranted. Identification of differential methylation
of the SAMSN1 promoter suggests that demethylating agents may be
clinically useful in the treatment of MM. Furthermore, investigation into
the biologic outcomes of SAMSN1molecular interactionsmay reveal novel
therapeutic targets for the treatment ofMM. Finally, further analysis of the
C57BL/KaLwRij genomemay provide key insights into genes that may be
involved in the initiation and/or progression of MM disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.07.002.
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